Terms: = Breast cancer AND NDRG1, NDR1, 10397, ENSG00000104419, Q92597, RIT42, CMT4D, TARG1, HMSNL, GC4, RTP, TDD5, PROXY1, NMSL, CAP43 AND Clinical Outcome
3 results:
1. TGFβ Governs the Pleiotropic Activity of ndrg1 in Triple-Negative breast cancer Progression.
López-Tejada A; Griñán-Lisón C; González-González A; Cara FE; Luque RJ; Rosa-Garrido C; Blaya-Cánovas JL; Navarro-Ocón A; Valenzuela-Torres M; Parra-López M; Calahorra J; Blancas I; Marchal JA; Granados-Principal S
Int J Biol Sci; 2023; 19(1):204-224. PubMed ID: 36594086
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic value of ndrg1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract] [Full Text] [Related]
3. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
Ross DT; Kim CY; Tang G; Bohn OL; Beck RA; Ring BZ; Seitz RS; Paik S; Costantino JP; Wolmark N
Clin Cancer Res; 2008 Oct; 14(20):6602-9. PubMed ID: 18927301
[TBL] [Abstract] [Full Text] [Related]
